Update
Eli Lilly Q3 Earnings Preview
Eli Lilly (LLY) is scheduled to release its Q3 2026 earnings before the U.S. market open on October 29, 2026. Wall Street consensus expects total revenue of approximately $22.6 billion, with adjusted EPS in the $5.7–$6.3 range. The market's main focus is on the growth of blockbuster drugs Mounjaro and Zepbound, and the ramp-up of the oral weight-loss drug Foundayo. Key items to watch include the impact of cash-pay price cuts and the Medicare Bridge program on U.S. volumes, and the potential for international growth, especially in China, to offset pricing pressure. The market expects revenue for Foundayo to rise to approximately $230 million in the current quarter.